The emergence of amivantamab offers a important development for individuals battling cancers with c-MET dysregulation. This novel molecule, a targeted agent of multiple MET kinase plus human epidermal growth factor https://orlandohzzl411017.wikicorrespondence.com/6648044/amivantamab_a_promising_hope_for_c_met_driven_cancers